| Progression-free survival following stereotactic body radiotherapy for oligometastatic prostate cancer treatment-naive recurrence: a multi-institutional analysis P Ost, BA Jereczek-Fossa, N Van As, T Zilli, A Muacevic, K Olivier, ... European urology 69 (1), 9-12, 2016 | 273 | 2016 |
| Androgen deprivation and high-dose radiotherapy for oligometastatic prostate cancer patients with less than five regional and/or distant metastases U Schick, S Jorcano, P Nouet, M Rouzaud, H Vees, T Zilli, O Ratib, ... Acta oncologica 52 (8), 1622-1628, 2013 | 182 | 2013 |
| Prediction of local and metastatic recurrence in solitary fibrous tumor: construction of a risk calculator in a multicenter cohort from the French Sarcoma Group (FSG) database S Salas, N Resseguier, JY Blay, A Le Cesne, A Italiano, C Chevreau, ... Annals of oncology 28 (8), 1779-1787, 2017 | 139 | 2017 |
| Metastasis-directed therapy in treating nodal oligorecurrent prostate cancer: a multi-institutional analysis comparing the outcome and toxicity of stereotactic body … E De Bleser, BA Jereczek-Fossa, D Pasquier, T Zilli, N Van As, S Siva, ... European urology 76 (6), 732-739, 2019 | 126 | 2019 |
| Pattern of progression after stereotactic body radiotherapy for oligometastatic prostate cancer nodal recurrences P Ost, BA Jereczek-Fossa, N Van As, T Zilli, A Tree, D Henderson, ... Clinical Oncology 28 (9), e115-e120, 2016 | 116 | 2016 |
| Standard of care versus metastases-directed therapy for PET-detected nodal oligorecurrent prostate cancer following multimodality treatment: a multi-institutional case-control … T Steuber, C Jilg, P Tennstedt, A De Bruycker, D Tilki, K Decaestecker, ... European urology focus 5 (6), 1007-1013, 2019 | 104 | 2019 |
| [(18) F] Fluoroethyltyrosine-positron emission tomography-guided radiotherapy for high-grade glioma DC Weber, T Zilli, F Buchegger, N Casanova, G Haller, M Rouzaud, ... Radiation Oncology 3, 1-11, 2008 | 100 | 2008 |
| Optimization of radiation therapy techniques for prostate cancer with prostate-rectum spacers: a systematic review G Mok, E Benz, JP Vallee, R Miralbell, T Zilli International Journal of Radiation Oncology* Biology* Physics 90 (2), 278-288, 2014 | 85 | 2014 |
| Metastatic prostate cancer: treatment options V Achard, PM Putora, A Omlin, T Zilli, S Fischer Oncology 100 (1), 48-59, 2022 | 81 | 2022 |
| Early esophageal cancer: the significance of surgery, endoscopy, and chemoradiation S Mönig, M Chevallay, N Niclauss, T Zilli, W Fang, A Bansal, J Hoeppner Annals of the New York Academy of Sciences 1434 (1), 115-123, 2018 | 81 | 2018 |
| ESTRO ACROP consensus guideline on the use of image guided radiation therapy for localized prostate cancer P Ghadjar, C Fiorino, PM af Rosenschöld, M Pinkawa, T Zilli, ... Radiotherapy and Oncology 141, 5-13, 2019 | 77 | 2019 |
| Recurrence pattern after [(18) F] fluoroethyltyrosine-positron emission tomography-guided radiotherapy for high-grade glioma: a prospective study DC Weber, N Casanova, T Zilli, F Buchegger, M Rouzaud, P Nouet, ... Radiotherapy and oncology 93 (3), 586-592, 2009 | 73 | 2009 |
| PEACE V–Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): A study protocol for a randomized controlled phase II trial A De Bruycker, A Spiessens, P Dirix, N Koutsouvelis, I Semac, ... BMC cancer 20, 1-12, 2020 | 70 | 2020 |
| Radiotherapy in the time of the Coronavirus pandemic: when less is better V Achard, P Tsoutsou, T Zilli Int J Radiat Oncol Biol Phys 107 (3), 600-601, 2020 | 69 | 2020 |
| Management of patients with advanced prostate cancer. Part I: intermediate-/high-risk and locally advanced disease, biochemical relapse, and side effects of hormonal treatment … S Gillessen, A Bossi, ID Davis, J de Bono, K Fizazi, ND James, N Mottet, ... European urology 83 (3), 267-293, 2023 | 67 | 2023 |
| Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: systematic review and consensus recommendations by the EORTC–ESTRO … SGC Kroeze, M Pavic, K Stellamans, Y Lievens, C Becherini, M Scorsetti, ... The lancet oncology 24 (3), e121-e132, 2023 | 66 | 2023 |
| Neoadjuvant chemoradiotherapy with radiation dose escalation with contact x-ray brachytherapy boost or external beam radiotherapy boost for organ preservation in early cT2–cT3 … JP Gerard, N Barbet, R Schiappa, N Magné, I Martel, L Mineur, ... The Lancet Gastroenterology & Hepatology 8 (4), 356-367, 2023 | 64 | 2023 |
| Whole‐body SPECT/CT versus planar bone scan with targeted SPECT/CT for metastatic workup O Rager, R Nkoulou, N Exquis, V Garibotto, C Tabouret-Viaud, H Zaidi, ... BioMed research international 2017 (1), 7039406, 2017 | 64 | 2017 |
| Nonsurgical salvage local therapies for radiorecurrent prostate cancer: a systematic review and meta-analysis G Ingrosso, C Becherini, A Lancia, S Caini, P Ost, G Francolini, M Høyer, ... European urology oncology 3 (2), 183-197, 2020 | 61 | 2020 |
| [68Ga] Ga-PSMA-11 in prostate cancer: a comprehensive review F Bois, C Noirot, S Dietemann, IC Mainta, T Zilli, V Garibotto, MA Walter American Journal of Nuclear Medicine and Molecular Imaging 10 (6), 349, 2020 | 61 | 2020 |
